SEARCH:   Advanced

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by List, A. F. Articles by Appelbaum, F. R. Search for Related Content PubMed PubMed Citation Articles by List, A. F. Articles by Appelbaum, F. R. Related Collections Neoplasia Brief Reports Clinical Trials and Observations Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  Blood, 1 September 2002, Vol. 100, No. 5, pp. 1910-1912 BRIEF REPORT Cyclosporine inhibition of P-glycoprotein in chronic myeloid leukemia blast phase Alan F. List, Kenneth J. Kopecky, Cheryl L. Willman, David R. Head, Marilyn L. Slovak, Dan Douer, Shaker R. Dakhil, and Frederick R. Appelbaum From the Arizona Cancer Center, Tucson. Chronic myeloid leukemia blast phase (CML-BP) cells commonly express the multidrug transporter, P-glycoprotein (Pgp). To determine whether Pgp inhibition improves treatment outcome in CML-BP, the Southwest Oncology Group performed a randomized, controlled trial testing the benefit of the Pgp modulator, cyclosporin A (CsA). Seventy-three eligible patients were assigned to treatment with cytarabine and infusional daunorubicin with or without intravenous CsA. Treatment with CsA yielded no improvement in treatment outcome as measured by the frequency of induction resistance (68% vs 53%), rate of complete remission or restored chronic phase (CR/CP, 8% vs 30%), and survival (3 vs 5 months). Blast expression of Pgp (63%) and LRP (71%) was common, whereas only Pgp adversely impacted the rate of CR/CP (P = .025). We conclude that Pgp has prognostic relevance in CML-BP but that the modulation of Pgp function with CsA as applied in this trial is ineffective. © 2002 by The American Society of Hematology.   CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: S Tsujimura, K Saito, M Nawata, S Nakayamada, and Y Tanaka Overcoming drug resistance induced by P-glycoprotein on lymphocytes in patients with refractory rheumatoid arthritis Ann Rheum Dis, March 1, 2008; 67(3): 380 - 388. [Abstract] [Full Text] [PDF] S. Tsujimura, K. Saito, K. Kohno, and Y. Tanaka Fragmented Hyaluronan Induces Transcriptional Up-regulation of the Multidrug Resistance-1 Gene in CD4+ T Cells J. Biol. Chem., December 8, 2006; 281(49): 38089 - 38097. [Abstract] [Full Text] [PDF] X.-f. Zhou, L. Zhang, E. Tseng, E. Scott-Ramsay, J. J. Schentag, R. A. Coburn, and M. E. Morris NEW 4-ARYL-1,4-DIHYDROPYRIDINES AND 4-ARYLPYRIDINES AS P-GLYCOPROTEIN INHIBITORS Drug Metab. Dispos., March 1, 2005; 33(3): 321 - 328. [Abstract] [Full Text] [PDF] S. Tsujimura, K. Saito, S. Nakayamada, K. Nakano, J. Tsukada, K. Kohno, and Y. Tanaka Transcriptional regulation of multidrug resistance-1 gene by interleukin-2 in lymphocytes Genes Cells, December 1, 2004; 9(12): 1265 - 1273. [Abstract] [Full Text] [PDF] D. Mahadevan and A. F. List Targeting the multidrug resistance-1 transporter in AML: molecular regulation and therapeutic strategies Blood, October 1, 2004; 104(7): 1940 - 1951. [Abstract] [Full Text] [PDF]

	Copyright © 2002 by American Society of Hematology         Online ISSN: 1528-0020